GlassScriptPhysician profile
Jason S Day
NPI 1427205038
$86,060.94
in general payments reported to CMS, 2019-2025
26 companies · $143 in 2025
The $143 reported for 2025 was less than what a typical Vascular Neurology provider received nationally (typical 2025 total: $360).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $3,541 · 2021: $7,685 · 2022: $30K · 2023: $28K · 2024: $6,123 · 2025: $143.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Travel and Lodging: $5,588 · Consulting Fee: $3,105 · Food and Beverage: $2,367 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,300.00 |
| Travel and Lodging | $5,588.06 |
| Consulting Fee | $3,105.00 |
| Food and Beverage | $2,367.05 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $33,737.02 | 2019-2024 | Amplatzer Talisman, Amplatzer Amulet |
| W. L. Gore & Associates, INC. | $29,730.75 | 2020-2024 | Gore Cardioform Septal Occluder |
| Astrazeneca Pharmaceuticals LP | $9,494.44 | 2021-2024 | Andexxa, Wainua |
| Medtronic, INC. | $5,019.42 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $3,047.83 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,903.20 | 2023 | |
| Astrazeneca Uk Limited | $891.82 | 2022 | |
| Medtronic Vascular, INC. | $497.56 | 2020 | |
| Portola Pharmaceuticals, LLC | $292.63 | 2019 | |
| Zimmer Biomet Holdings, INC. | $199.63 | 2020-2022 | |
| Genzyme Corporation | $157.44 | 2020-2025 | |
| Penumbra, INC. | $148.79 | 2024 | Penumbra System |
| Silk Road Medical, INC. | $135.94 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Microvention, INC. | $122.16 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $111.44 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $106.95 | 2020 | |
| Johnson & Johnson Surgical Vision, INC. | $91.44 | 2025 | Tecnis Simplicity, Veritas Vision System |
| Merck Sharp & Dohme LLC | $76.27 | 2019 | |
| Argenx US, INC. | $69.87 | 2024 | Vyvgart Hytrulo |
| Lilly USA, LLC | $47.76 | 2024 | Amyvid |
| Csl Behring | $44.80 | 2024 | Kcentra |
| Microtransponder, INC. | $41.94 | 2022 | |
| Eisai INC. | $24.90 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $24.31 | 2023 | Nuedexta |
| Azurity Pharmaceuticals, INC. | $23.47 | 2023 | Horizant |
| Kerecis Limited | $19.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.